Miles Wang, OpenAI Researcher, Launches AI-Driven Drug Discovery Startup Amid $2B Funding Hype
Miles Wang, a former OpenAI researcher known for advancing AI in scientific discovery, is set to launch a startup focused on AI-driven drug development, according to multiple sources. The venture, which could secure $200 million at a $2 billion valuation, reflects growing investor confidence in AI’s potential to revolutionize life sciences, according to TechCrunch.
Miles Wang’s New Venture in AI-Driven Drug Discovery
Wang, who joined OpenAI in 2024 after leaving Harvard, co-authored research on AI’s role in accelerating scientific discovery. His new company, which has not yet been officially named, is reportedly targeting repurposing existing drugs and identifying new applications for compounds that failed clinical trials, a strategy that could cut development timelines significantly, TechCrunch reported.
“Finding new uses for FDA-approved drugs can result in faster time to revenue than developing new drugs from scratch,” one source told TechCrunch. Wang has disputed the reported funding figures, though he did not provide specifics, according to the outlet.
Investor Interest in AI for Life Sciences
The proposed funding round, led by venture firm Lightspeed, underscores a broader trend of AI-focused life science startups securing massive investments. Chai Discovery, a two-year-old company using AI to predict molecular interactions, recently raised $400 million at a $3.8 billion valuation, Chai Discovery’s website confirmed. Meanwhile, Google DeepMind spinout Isomorphic Labs secured $2.1 billion in May 2023 for its drug discovery efforts, Isomorphic Labs’ website states.
Context: Young Founders and Venture Capital Trends
Wang’s departure from OpenAI aligns with a shift in venture capital toward young, college-dropout founders.
Challenges and Opportunities in AI Drug Discovery
Despite the optimism, challenges remain.
Wang’s startup faces the task of proving that its AI models can consistently identify viable drug candidates.
What’s Next for the AI-Drug Discovery Sector?
As Wang’s startup moves forward, it will join a competitive landscape dominated by established players and emerging innovators. The success of companies like Chai Discovery and Isomorphic Labs suggests that AI-driven drug discovery is no longer a niche experiment but a mainstream investment focus. However, the sector’s long-term viability will depend on demonstrating tangible outcomes, such as approved drugs or cost-saving efficiencies.